Anytime I stumble upon a biotech company that uses digital technology instead of drugs to help patients feel or get better, I’m a big fan. I love what Dthera is all about!
Please watch this video:
Dthera Sciences, based in San Diego, CA, is a Digital Therapeutics company focused on developing innovative digital quality of life therapies for neurodegenerative diseases and oncology. The Company’s lead product, ReminX, is an artificial-intelligence-powered digital therapeutic designed to reduce anxiety and improve quality of life in patients with Alzheimer’s disease and Dementia. Alzheimer’s disease is the 6th leading cause of death in the United States. Currently, more than 5 million Americans are living with Alzheimer’s disease in the United States alone. In 2017, the direct cost to American society of caring for those with Alzheimer’s disease and other dementias will total an estimated $259 billion.
Digital Therapeutics is a new subsection of digital health that strives to directly deliver a therapy via use or interaction with software technology. The goal of Digital Therapeutics is to mirror an effective treatment and use technology to scale it to a larger patient population, thereby amplifying doctors’ and nurses’ care, changing patient behavior, and most importantly, reducing cost of care.
CEO Edward Cox has assembled a very powerful team to assist in bringing the Dthera technology to the forefront.
Without a doubt, 2018 will be a huge year for the company.
IBR will have a full report on Dthera very soon.
In the meantime, get long!
Market Cap: $28.8M
52 Week Range: 0.60 – 30.00
Shares Outstanding: 48,304,934